Valid for Submission
D46.20 is a billable diagnosis code used to specify a medical diagnosis of refractory anemia with excess of blasts, unspecified. The code D46.20 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
The ICD-10-CM code D46.20 might also be used to specify conditions or terms like refractory anemia with excess blasts .
Unspecified diagnosis codes like D46.20 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.
Tabular List of Diseases and Injuries
The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized "head to toe" into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code D46.20:
Inclusion TermsInclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
- RAEB NOS
Index to Diseases and Injuries
The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code D46.20 are found in the index:
- - Anemia (essential) (general) (hemoglobin deficiency) (infantile) (primary) (profound) - D64.9
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Refractory anemia with excess blasts
- ANEMIA REFRACTORY WITH EXCESS OF BLASTS-. chronic refractory anemia with granulocytopenia and/or thrombocytopenia. myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
Diagnostic Related Groups - MS-DRG Mapping
|MS-DRG||MS-DRG Title||MCD||Relative Weight|
|811||RED BLOOD CELL DISORDERS WITH MCC||16||1.3776|
|812||RED BLOOD CELL DISORDERS WITHOUT MCC||16||0.8797|
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.
Convert D46.20 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code D46.20 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.
Information for Patients
Your bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. It contains immature cells, called stem cells. The stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting. If you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. Many of them die in the bone marrow. This means that you do not have enough healthy cells, which can lead to infection, anemia, or easy bleeding.
Myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. If you have symptoms, they may include
- Shortness of breath
- Weakness or feeling tired
- Skin that is paler than usual
- Easy bruising or bleeding
- Pinpoint spots under the skin caused by bleeding
- Fever or frequent infections
Myelodysplastic syndromes are rare. People at higher risk are over 60, have had chemotherapy or radiation therapy, or have been exposed to certain chemicals. Treatment options include transfusions, drug therapy, chemotherapy, and blood or bone marrow stem cell transplants.
NIH: National Cancer Institute
[Learn More in MedlinePlus]